无处不在的途径是帕金森病的核心吗?
Benoit I Giasson1, Virginia M-Y Lee
1Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Cell
|July 16, 2003
概括
帕金森病 (PD) 涉及到特定脑细胞的损失. 蛋白质降解通过ubiquitin-proteasome系统受损可能是这种神经退行性疾病发展的关键因素.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 分子生物学分子生物学
- 神经学 神经学
背景情况:
- 帕金森病 (PD) 是一种流行的神经退行性运动障碍.
- 患PD的运动缺陷源于黑质体中多巴胺能神经元的损失.
- 驱动这种神经元损失的精确机制仍然不完全理解.
研究的目的:
- 研究蛋白质降解途径在帕金森病病因学中的作用.
- 为了探索ubiquitin-proteasome系统功能障碍和帕金森症之间的联系.
主要方法:
- 关于蛋白质降解机制的最近研究的综述.
- 分析证据,将蛋白质酶功能与神经退行症联系起来.
- 检查参与神经元细胞死亡的生化途径.
主要成果:
- 在某些形式的帕金森症中,泛奎丁介导的蛋白酶体功能的改变或减少与帕金森症有关.
- 有证据表明,蛋白质降解在PD的潜在原因中起着重要作用.
结论:
- 无素-蛋白酶体系统是帕金森病发病的关键因素.
- 对蛋白酶功能的进一步研究可能会揭示PD的新治疗点.
更多相关视频
相关概念视频
The Proteasome
7.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.8K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology
26
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
26


